AKT1 and plasma cell myeloma: PD-1 was observed to induce drug resistance via the AKT signaling pathway in myeloma cells.[32] Additionally, the PI3K/AKT inhibitors could reduce the PD-1/PD-L1's induced resistance to antitumor agents.[32] The clinical data have shown that PD-L1 is important for immune evasion by tumor cells.